American Trust’s VanEck Biotech ETF BBH Stock Holding History

American Trust’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,342	Closed	-$385K	–	296
2023 Q2	$385K	Hold	2,342	–	–	0.03%	250
2023 Q1	$385K	Sell	2,342 -19	-0.8%	-$3.07K	0.03%	258
2022 Q4	$377K	Buy	2,361 +33	+1%	+$5.23K	0.04%	270
2022 Q3	$368K	Buy	+2,328	New	+$352K	0.03%	259

Other funds holding BBH

MIM

Miller Investment Management West Conshohocken, Pennsylvania $1.01B AUM 13.96% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

CIG

Consolidated Investment Group Englewood, Colorado $922M AUM 28.87% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

American Trust's BBH Position: Q3 2023 in Review

American Trust sold out of VanEck Biotech ETF (BBH) in Q3 2023, closing a stake of 2,342 shares — an estimated $385K sold.

American Trust first reported a position in BBH in Q3 2022 and held it in 4 quarters. The position peaked at $385K in Q2 2023. 110 funds tracked by Wall St. Rank hold BBH as of Q3 2023.

American Trust reported no remaining VanEck Biotech ETF position as of Q3 2023 after selling out during the quarter.
American Trust sold 2,342 VanEck Biotech ETF shares in Q3 2023, an estimated $385K.
American Trust first reported a position in VanEck Biotech ETF in Q3 2022 and held it in 4 quarters.
American Trust's VanEck Biotech ETF position peaked at $385K in Q2 2023.
110 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q3 2023.

Based on American Trust's 13F filing for Q3 2023, filed 15 Nov 2023.